Cytokinetics Announces Proposed Public Offering of Common Stock
Cytokinetics announced a proposed underwritten public offering of approximately $650 million of common stock, subject to market conditions. The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold. Morgan Stanley, Goldman Sachs, J.P.
Key figures
- Deal Value Usd
- approximately $650 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.